文献速递重症综合管理与镇静镇痛儿科与产科急症

照顾者路径干预对重症患者家属创伤后应激障碍症状的影响:随机对照试验长期结果

Effects of The Caregiver Pathway intervention on symptoms of post-intensive care syndrome among family caregivers to critically ill patients: long-term results from a randomized controlled trial.
PubMed 文献 · Intensive Care Med · 2025-10-06
一句话结论单中心随机对照试验显示,照顾者路径干预可降低重症患者家属6个月时PTSD症状(IES-R评分25.8 vs 30.9),对存活患者家属12个月时PTSD和焦虑症状亦有显著效果。

该研究为单中心非盲随机对照试验,纳入196名重症患者家属,随机分为干预组(n=101)和对照组(n=95)。照顾者路径干预包括ICU早期数字评估后与护士对话、转出ICU时支持卡、转至降阶梯病房后电话随访、出院后3个月内随访对话。主要结果显示,6个月时干预组PTSD症状IES-R评分显著低于对照组(25.8 vs 30.9,p=0.009),12个月时呈边缘显著趋势(25.0 vs 28.4,p=0.057)。亚组分析显示,在存活患者家属中,12个月时干预组PTSD(IES-R 19.8 vs 29.1,p=0.001)和焦虑(HADS-A 4.3 vs 6.8,p=0.003)评分均显著低于对照组。结论认为照顾者路径有潜力减轻PICS-F症状,尤其是患者存活的家眷。

要点

  • 6个月时干预组PTSD症状IES-R评分25.8(95%CI 21.9-29.7)vs 对照组30.9(95%CI 26.7-35.0),p=0.009。
  • 12个月时干预组IES-R评分25.0(95%CI 21.3-28.7)vs 对照组28.4(95%CI 24.1-32.7),p=0.057,呈边缘显著趋势。
  • 存活患者家属亚组12个月时干预组PTSD评分19.8(95%CI 15.3-24.2)vs 对照组29.1(95%CI 23.5-34.6),p=0.001。
  • 存活患者家属亚组12个月时干预组焦虑HADS-A评分4.3(95%CI 3.1-5.4)vs 对照组6.8(95%CI 5.2-8.4),p=0.003。
  • 干预包括ICU早期数字评估后与护士对话、转出ICU时支持卡、转降阶梯病房后电话随访、出院后3个月内随访对话。

适用人群与场景

  • 重症患者家属(照顾者),共196名,随机分为干预组101名和对照组95名。
  • 单中心研究,非盲设计。

处置流程与药物剂量

  • 第一步:ICU最初几天内进行数字评估,随后与护士对话。
  • 第二步:离开ICU时给予支持卡。
  • 第三步:患者转至降阶梯病房后,提供电话随访。
  • 第四步:出院后3个月内进行随访对话。

研究设计与关键结果

  • 研究类型:单中心非盲随机对照试验,样本量196名家属(干预组101名,对照组95名)。
  • 主要终点:6个月时PTSD症状IES-R评分干预组25.8(95%CI 21.9-29.7)vs 对照组30.9(95%CI 26.7-35.0),p=0.009。
  • 12个月时IES-R评分干预组25.0(95%CI 21.3-28.7)vs 对照组28.4(95%CI 24.1-32.7),p=0.057。
  • 亚组分析(12个月,存活患者家属):PTSD的IES-R评分干预组19.8(95%CI 15.3-24.2)vs 对照组29.1(95%CI 23.5-34.6),p=0.001;焦虑HADS-A评分干预组4.3(95%CI 3.1-5.4)vs 对照组6.8(95%CI 5.2-8.4),p=0.003。
  • 其他结局指标包括抑郁、健康相关生活质量、希望和自我效能,原文未报告具体结果数值。

证据类型、等级与局限

  • 证据类型:单中心非盲随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为照顾者路径有潜力减轻PICS-F症状,尤其是患者存活的家眷。
  • 该干预包括ICU期间护士对话、转出时支持卡、转病房后电话随访和出院后3个月内随访对话,可供ICU团队参考实施。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: A long-term evaluation of The Caregiver Pathway, a model to follow up family caregivers on Post-intensive Care Symptoms among Family (PICS-F).

METHODS: A single-center non-blinded randomized controlled trial including 196 family caregivers to critically ill patients randomized to intervention (n = 101) or control group (n = 95). The Caregiver Pathway intervention consists of: (1) a digital assessment followed by a conversation with a nurse in the first days at the ICU, (2) a supportive card when leaving the ICU, (3) an offer to receive a phone call following patient transfer to a step-down unit, and (4) a follow-up conversation within 3 months after discharge. Outcome measures were collected at 6 and 12 months, including symptoms of post-traumatic stress disorder (PTSD), anxiety, depression, Health-related Quality of Life (HRQoL), hope, and self-efficacy.

RESULTS: The Caregiver Pathway was associated with a significant effect for symptoms of PTSD after 6 months compared with controls, mean IES-R score: 25.8 [95% CI 21.9-29.7] versus 30.9 [95% CI 26.7-35.0], p = 0.009, and a trend toward an effect after 12 months: IES-R score: 25.0 [95% CI 21.3-28.7] versus 28.4 [95% CI 24.1-32.7], p = 0.057. Subgroup analyses at 12 months showed a significant intervention effect among family caregivers of patients who survived compared to controls for PTSD, IES-R score: 19.8 [95% CI 15.3-24.2] versus 29.1 [95% CI 23.5-34.6], p = 0.001, and anxiety, HADS-A score: 4.3 [95% CI 3.1-5.4] versus 6.8 [95% CI 5.2-8.4], p = 0.003.

CONCLUSIONS: The Caregiver Pathway has the potential to reduce the symptoms of PICS-F, especially among family caregivers whose patient has survived.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Watland S, Solberg Nes L, Ekeberg Ø, et al. Effects of The Caregiver Pathway intervention on symptoms of post-intensive care syndrome among family caregivers to critically ill patients: long-term results from a randomized controlled trial. Intensive Care Med. 2025. PMID: 41051554. doi:10.1007/s00134-025-08139-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。